2023

Inspire Patient Experience Report

Market Surveillance & Quality Update

Inspire

Sleep Apnea Innovation

Overview:

Every Obstructive Sleep Apnea (OSA) patient experience is different, but one aspect rings true for all; it's excruciating to live with and ultimately manage. When it comes to OSA treatment, Continuous Pulmonary Air Pressure (CPAP) is the standard of care. While it works for many, it doesn't always work for everyone. When this happens, patients often feel like they're out of options and luck.

Inspire is a potential solution for these people. It is surgically implanted and tailored to the patient by a sleep medicine professional. The patient controls therapy with a small remote. Thousands of patients count on Inspire for relief from OSA.

Since 2007, successful patient outcomes and care experiences are guiding tenants for Inspire Medical Systems. Dr. Glen Nelson, Inspire Medical Systems' first Board Chairman, established the motto, "If we put the patient first, we will never lose our way." This spirit guides us each day. It motivated us to publish this Patient Experience Report (PER). This report transparently shares therapy outcomes through a patient lens and aims to educate the reader on the experiences of others.

For a full bibliography of over 250 peer reviewed publications covering Inspire, visit professionals.inspiresleep.com/publications.

Commitment to Quality

At Inspire Medical Systems, our focus on successful patient outcomes is paramount in everything we do each day. Our Quality Policy is our formal commitment to you that we will never waver in that regard.

Inspire Quality Policy:

- **Relentlessly** pursue safe, effective, and reliable treatment of obstructive sleep apnea.
- **Strive** to consistently improve the quality of life of our patients and exceed customer expectations.
- **Maintain** rigorous processes that ensure compliance with applicable global laws and regulations.

There are two primary data sources for the Inspire PER system.

1. Post-market surveillance data
2. ADHERE, real-world global registry



Dr. Glen D Nelson
Inspire Chairman of the Board
2006–2017

"Put the patient first and you will never lose your way."

Contact Information

Feedback plays a vital role in our effort to continuously improve our products and services. To contact our patient and physician support team, please visit inspiresleep.com/contact for 24x7 support or call 1-844-672-4386 (US) or +49 0800 00 09 78 99 (EU).



Andrea Rasmussen
Vice President, Quality
Inspire Medical Systems, Inc.

Contents

Post Market Surveillance System Overview

Post market surveillance is a systemic process used to collect and analyze experience gained from medical devices that have been commercially approved and placed on the market.

Post market experience data is collected from patients, healthcare professionals, product registries, regulators and Inspire employees.

A post market surveillance system has many critical inputs and outputs, as illustrated below.

Post market surveillance system

Proactive Data Sources
- Post Market Clinical Studies
- Literature Searches
- Product Service Data
- Customer Surveys
- Social Media

Reactive Data Sources
- Complaints
- Regulatory Safety Reports
- Non-conformance Reports
- Out-of-Tolerance Reports
- Audits

Data Signals Drive:
- Corrective & Preventive Action
- Training
- Design Improvements
- Product Recalls



Inspire Medical Systems uses both proactive and reactive data to monitor the performance of our products.

Data is collected from Inspire Medical Systems customers around the world. Data analysis from these sources may lead to corrective action, regulatory reporting, improvements to our products, and training.

Post market surveillance data is collected from customer and patient-initiated complaints, product returns and Inspire employee reports. Underreporting of events is recognized throughout the medical device industry. Inspire Medical Systems is continuously improving the accuracy of the data through rigorous and regular employee training and customer awareness.

ADHERE Registry Overview

- Goal: Collect **real-world outcomes** data
- International multi-center, standard-of-care registry
- Eligibility – patients receiving Upper Airway Stimulation (UAS) for OSA

5,000 enrollments at 61 medical centers

US Centers

EU Centers (Belgium, Germany, Netherlands, Switzerland)

Registry Data Collection

Baseline

Medical Record
- Demographics
- OSA History
- AHI
- ESS

Implant
- Implant Time
- Adverse Events

Post-Titration (6mo.)
- AHI
- ESS
- Patient Experience
- Therapy Usage
- Clinical Global Impression

Annual Visit (12mo.)
- AHI
- ESS
- Patient Experience
- Therapy Usage
- Clinical Global Impression

AHI = Apnea Hypopnea Index
ESS = Epworth Sleepiness Scale

Patient Satisfaction

Patient satisfaction is a result of clinical outcomes, patient experience, and quality of life. It is a measure of the timely, efficient, and patient-centered delivery of quality care. Patient satisfaction is thus a very important indicator to measure the success of Inspire.

The ADHERE registry asks patients to answer four questions about their satisfaction with Inspire.

How does Inspire compare against your previous experience with CPAP?	**91%**[1]	**Say Inspire is better**
I would recommend Inspire to a friend or family member.	**93%**[1]	**Agree or strongly agree**
Given the chance, I would choose to receive Inspire again.	**92%**[1]	**Agree or strongly agree**
Overall, how satisfied are you with Inspire?	**90%**[1]	**Satisfied or very satisfied**

Quality of Life & Compliance

The Epworth Sleepiness Scale (ESS) is currently the most used subjective test of daytime sleepiness in clinical practice. It is a simple, self-administered, eight-item questionnaire that measures the risk of falling asleep in eight specific situations that are commonly met. A score of less than 10 is considered as normal. The higher the score (from 10 to 24) the greater the reported subjective daytime sleepiness (Johns, 1991).

The ADHERE registry asks patients to complete an ESS survey at baseline and at 6 and 12-month follow-ups. ESS is the measure Inspire uses to quantify subjective benefit of therapy. Prior to Inspire, patients were sleepy, and sleepiness is reduced to normal levels after treatment.



Compliance to therapy is a key factor required to gain the health benefits associated with treating obstructive sleep apnea. Longer CPAP usage has been shown to improve survival, cardiovascular events, blood pressure, excessive daytime sleepiness, cognitive function, and quality of life. However, average compliance to CPAP is often reported at less than 5 hours[2-3].

The ADHERE registry tracks average nightly compliance of Inspire patients.

Hours of nightly use @ 12-months (n=913[1])

5.7

UAS usage of 5.7 hours/night at 12-months exceeds average CPAP usage levels from major clinical studies. [2-3]

1 Bosschieter et al. Similar effect of hypoglossal nerve stimulation for OSA in five disease categories. J Clin Sleep Med. 2022 Jun 1;18(6):1657-166.
2 Apnea Positive Pressure Long-term Efficacy 1: Study—Kushida et al, SLEEP, Vol. 35, No. 12, 2012
3 The HOME-PAP Study —Rosen et al, SLEEP, Vol. 35, No. 6, 2012

OSA Burden Reduction

The apnea-hypopnea index (AHI) is well established as the best studied metric of OSA severity. The AASM has identified the following severity grades based on the number of obstructive breathing events per hour:

- Mild: 5 to 15 events per hour
- Moderate: 15 to 30 events per hour
- Severe: greater than 30 events per hour

The ADHERE registry includes a PSG titration study at six months and a follow-up PSG or HSAT at 12 months.



Surgical Revision & Device Explant Results

Inspire monitors and collects post market surveillance data on surgical revisions and device explants. Our historical and go-forward improvements in product and patient outcomes are real and measurable. Year over year improvements are driven by:

- Continuous training and improvement to surgical technique
- Improved Inspire Medical Systems field support training
- Elective explant rates decreasing with improved patient selection
- Published post implant patient care pathways
- Regulatory approval of expanded labeling

Post Market Surveillance (Revision Rates)

Figure 1: Freedom from Inspire System Revision by Implant Year[4]



2022 Primary Reasons for Revision:

- **Device Movement** (device migration, erosion, tethering)
- **Device Deficiency** (related to the respiratory sensing lead or IPG)
- **Post-surgical Healing** (hematoma, incision dehiscence, scar tissue removal)

Top 3 reasons account for 71% of total revisions.

A device revision is a surgical event where a patient requires that an implanted system component be replaced or a surgical intervention is necessary to remedy an adverse event or patient complaint.

Post Market Surveillance (Explant Rates)

Figure 2: Freedom from Inspire System Explant by Implant Year



2022 Primary Reasons for Explant:

- Elective Explant
- Infection
- MRI Compatibility

Top 3 reasons account for 91% of total explants.

A device revision is a surgical event where a patient removal of the entire implanted system or removal of an implanted system component.

[4] Huntley, et al. Real-World Evaluation of Upper Airway Stimulation System Survival Using Post-Market Surveillance Data. [Poster abstract]. SLEEP 2023 Conference.

Figures 1 and 2 (on the preceding page) show the percentage of implanted patients that remain free from revision or explant-related events at various time points post implant. These are estimated using the Kaplan-Meier statistical method. These estimates intend to illustrate the probability that a patient is free from a surgical revision or device explant related event for a given number of years. As an example, a probability percentage of 97% indicates that through the stated follow-up time, the patient had a 3% risk of a surgical revision or device explant since the time of initial implant.

These statistical curves are estimates based on internal quality reporting systems. As our experience accumulates, the accuracy of the estimation improves.

In 2022, Inspire's post market surveillance system (illustrated earlier) revealed three (3) specific product quality trends requiring corrective actions.

1. **Respiratory Sensing Lead – Tip Failure:** This results in a revision surgery for a small number of patients because the sensing lead tip separated from the primary lead body. Three specific action items were formally implemented to mitigate this risk in 2021:
   - Best practice surgical training on the handling and insertion of the lead
   - An improved surgical technique for implanting the sensing lead; specifically, moving from a 3-incision procedure to a 2-incision procedure
   - Acknowledgment of possible sensing lead interactions with patient anatomy

   Implementation of these mitigations decreased the reported occurrence rate of this issue in patients post mitigation from approximately 1.1% (1 in 90 procedures) to 0.07% (1 in 1,400 procedures).

2. **Respiratory Sensing Lead – Damage:** The surgical training update noted above facilitates a review of each patient's diagnostic data during routine in-office visits. In a small number of patients, a revision surgery is required as the lead insulation is damaged and is detectable during check-up. Most revisions are related to the Inspire Model 4323 Respiratory Sensing Lead which is no longer manufactured. The Inspire Model 4340 Respiratory Sensing Lead, currently in production, is more robust and designed specifically to mitigate this risk.

3. **Stimulation Lead – Manufacturing Defect:** Inspire launched a new version of its' Model 4063 Stimulation Lead in the United States in late 2022. During the early patient experience, Inspire encountered difficulty with the new manufacturing process. In response, Inspire initiated a non-patient safety related, voluntary market withdrawal to remove three hundred fifty-three (353) Model 4063 Stimulation Leads, manufactured in late 2022, from various healthcare facilities. Inspire subsequently improved the overall manufacturing process through the corrective and preventive action process. As a result, the performance of this product now meets Inspire's high expectations for robust product design and quality measures.

Intraoperative Complications – ADHERE Registry

The ADHERE registry monitors serious adverse events (SAE) during the procedure to place Inspire. Less than a half of a percent of implant procedures result in serious adverse events.

SAE Type[5]	# of Events	% of Patients
Hematoma	2	<0.1%
Infection	1	<0.1%
Failed Implant	1	<0.1%
Pneumothorax	1	<0.1%
Other	3	0.16%
Total	**8**	**0.43%**

Postoperative Complications – ADHERE Registry

The ADHERE registry also monitors serious adverse events (SAE) and other complications during the post-implant follow-up period. The most frequent complication is stimulation related discomfort which is more commonly observed at the 6-month post-titration visit compared to the 12-month final visit.

SAE Type[5]	# of Events	% of Patients
System explant (2 or more components)	1	<0.1%
System revision (2 or more components)	3	0.16%
Sensor lead revision	13	0.7%
Stimulation lead revision	12	0.64%
IPG Pocket revision	2	0.11%
Other	4	0.16%
Total	**35**	**1.9%**

The most frequent complication is therapy-related discomfort, which is more commonly observed at the 6-month post-titration visit compared to the 12-month final visit. Of patients with 12-month follow-up data, 19% reported some therapy-related discomfort which was most commonly presented as stimulation discomfort, insomnia/arousal or tongue abrasion.

Complication Type[5]	# of Events	% of Patients
Stimulation related discomfort	151	8.2%
Insomnia/Arousal	66	3.6%
Tongue abrasion	63	3.4%
Other non-serious events	69	3.7%
Total	**349**	**18.9%**

[5.] Suurna et al, ADHERE Registry 2020 Update, Laryngoscope, 00:1=9, 2021

Comparison to Anatomy Altering OSA Surgery – Third Party Data

There are other CPAP alternatives available for moderate to severe OSA patients, including anatomy-altering surgeries. Nord, et. al evaluated readmissions and complications following Inspire Upper Airway Stimulation (UAS) compared to palatal or multilevel sleep surgery. Both hospital readmission and complications following the procedure were significantly lower in the UAS group compared to anatomy altering surgeries. This information is included in the Inspire Patient Experience Report to provide a reference point for the complication rates seen with the Inspire procedure.

Readmission Following Procedure[6]



- Palatal surgery had a higher risk of readmission or return to OR (12%vs 4%, p<0.0001), and a higher complication rate (21% vs 2%, p<0.0001) than Inspire
- Multilevel surgery results had a similarly higher risk of readmission / return to OR (12% vs 4%, p<0.0001, complications: 22% vs 3%, p<0.0001)

Complications Following Procedure



The first 10 days following surgery was most risky for readmission for both palate and multilevel surgeries, but the Inspire group had very few complications, measured out to 90 days

[6] Nord R, Fitzpatrick T, DeShazo JP, Reiter ER. Comparison of readmission and complication rates between traditional sleep surgery and hypoglossal nerve stimulation. Laryngoscope Investig Otolaryngol. 2022;7(5):1659-1666.